Mozambique Operational Plan Report Fy 2013

Publisher Marketing: As part of our two year Country Operational Plan (COP), the 2013 plan supports the global priorities set forth in the AIDS-Free Generation (AFG) policy to: provide antiretroviral treatment (ART) for 6 million people; perform 4.7 million voluntary medical male circumcision (VMMC) procedures; provide antiretroviral (ARV) prophylaxis to 1.5 million HIV-infected pregnant women to prevent mother-to-child transmission (PMTCT); support the Government of Mozambique's (GRM) national "HIV/AIDS Acceleration Plan 2013-2015" (Acceleration Plan) to increase the percentage of eligible adults and children with advanced HIV infection who receive antiretroviral therapy to 80%; increase the percentage of HIV-positive pregnant women who receive ARVs to 90%; and increase the percentage of adult males circumcised in target provinces to 75% by 2015. The Acceleration Plan, developed in collaboration with the PEPFAR Mozambique team, and closely coordinated with the development of the Ministry of Health's Global Fund Round 9 phase II application for HIV/AIDS, prioritizes high-impact interventions and geographic areas, and focuses on a continuum of response by addressing key populations. This year's COP represents result-driven and target-based budget allocations through direct application of PEPFAR Expenditure Analysis and other unit cost data to PEPFAR's contribution to the national targets. Our interventions target priority districts identified in the GRM's Acceleration Plan and ensure strong linkages between counseling and testing, care, treatment, and PMTCT for a robust continuum of response. Our overall budget is carefully aligned to the priorities of an AIDS Free Generation. Prevention activities represent 24% of our overall budget, with 8% allocated to PMTCT for ARV prophylaxis for 61,147 pregnant women, 8% allocated to VMMC to circumcise 224,413 men, 3% reserved for sexual prevention to reach most-at-risk populations (MARPs), 4% dedicated to test and counsel 2.2 million individuals; 33% allocated for antiretroviral (ART) treatment for 380,680 adults and children - including 16% for ARV drugs, 19% dedicated to the care of almost one million HIV infected adults and children - including 10% for orphans and vulnerable children, and 13% budgeted for system strengthening activities to support prevention, care, and treatment goals. HIV commodities, including ARV drugs, represent 23% of the budget. USG management and operations represent 11% of PEPFAR resources.